Septerna, Inc. Operating Cash Flow
Septerna, Inc. (SEPN) reported Operating Cash Flow of -$47.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Septerna, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$22.18M.
- Septerna, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$25.63M.
- Septerna, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$14.99M.
- Septerna, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $168.81M.
- Septerna, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $110.19M.
- Septerna, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$67.47M.
- Septerna, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$38.72M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$47.81M 10-Q · filed 2026-08-10 | -$62.80M derived: sum of 3 quarters · filed 2026-08-10 | $106.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$25.63M 10-Q · filed 2026-05-11 | -$40.62M derived: sum of 2 quarters · filed 2026-05-11 | $128.19M derived: sum of 3 quarters · filed 2026-05-11 | $107.90M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$14.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $153.82M derived: sum of 2 quarters · filed 2026-03-09 | $133.53M derived: sum of 3 quarters · filed 2026-08-10 | $110.19M 10-K · filed 2026-03-09 |
| 2025-09-30 | $168.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $148.52M derived: sum of 2 quarters · filed 2026-08-10 | $125.18M 10-Q · filed 2025-11-10 | $104.22M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$20.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$43.63M 10-Q · filed 2026-08-10 | -$64.59M derived: sum of 3 quarters · filed 2026-08-10 | -$81.40M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$23.34M 10-Q · filed 2026-05-11 | -$44.30M derived: sum of 2 quarters · filed 2026-05-11 | -$61.12M derived: sum of 3 quarters · filed 2026-05-11 | -$74.10M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$20.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$37.77M derived: sum of 2 quarters · filed 2026-03-09 | -$50.76M derived: sum of 3 quarters · filed 2026-03-09 | -$67.47M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$16.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$29.80M derived: sum of 2 quarters · filed 2025-11-10 | -$46.51M 10-Q · filed 2025-11-10 | -$55.31M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$12.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$29.70M 10-Q · filed 2025-08-11 | -$38.49M derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$16.71M 10-Q · filed 2025-05-15 | -$25.51M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$38.72M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$29.93M 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |